Director, Program Management
Crescent Biopharma
Director, Program Management
Crescent Biopharma
Clinical-stage biotech developing solid-tumor therapies
Position Overview
The Director, Program Management (PM) will play a vital role in a high-performing cross-functional Program Team. The PM is responsible for a wide range of activities, including facilitating and driving execution across the drug development lifecycle. Working in partnership with the Program Team Leader (PTL) and functional experts, the PM is responsible for developing a fully-integrated program plan supported by functional plans to deliver the strategic objectives of the program. The PM drives team execution to deliver program goals. Proposing and evaluating options to balance the key priorities of quality, speed, and cost, the PM encourages robust dialog within the team and facilitates arriving at team decisions. Clear and effective communication within the team and with company leadership is a key responsibility of the PM, working in concert with the PTL. The PM is solutions-oriented and comfortable operating amid ambiguity in a fast-paced environment. With the PTL, the PM frames and facilitates effective discussions to achieve alignment and data-driven decision-making. The PM builds durable, trust-based relationships with team members and stakeholders across the organization and effectively manages with influence.
What We Offer
Please note:
Crescent Biopharma is an Equal Opportunity Employer. We are committed to fostering a diverse, inclusive, and equitable workplace where all individuals are valued and respected. Employment decisions are based on qualifications, merit, and business needs, without regard to race, color, religion, gender, sexual orientation, national origin, disability, veteran status, or any other protected status.
Please note, Crescent does not accept unsolicited resumes from external agencies or recruiters. Submission of a resume without a prior written agreement does not create any express or implied contract between Crescent and the agency. Crescent will not pay any fees related to unsolicited resumes.
#LI-CBIO
Clinical-stage biotech developing solid-tumor therapies
Crescent Biopharma develops oncology therapies for solid tumors, led by CR-001, a tetravalent bispecific antibody that blocks PD-1 and VEGF to boost anti-tumor immunity while inhibiting tumor blood vessel growth. CR-001 sits in a global Phase 1/2 ASCEND trial, and the pipeline also includes CR-002, an anti-PD-L1 antibody-drug conjugate, and CR-003, an ITGB6-targeted ADC. The company differentiates itself by combining immune checkpoint blockade with VEGF inhibition and other targeted modalities to build an immuno-oncology backbone for solid tumors, supported by strategic partnerships and substantial private placements. Crescent’s goal is to advance multi-agent regimens toward regulatory approval and commercial development for patients with solid tumors.
Explore more opportunities at Crescent Biopharma